^
Association details:
| Biomarker: | BRCA1 mutation |
|---|---|
| Cancer: | Ovarian Cancer |
| Drug: | elimusertib (BAY 1895344) (ATR inhibitor) |
| Direction: | Sensitive |
Evidence:
Source:
Title:
First-in-Human Trial of the Oral Ataxia Telangiectasia and Rad3-Related Inhibitor BAY 1895344 in Patients with Advanced Solid Tumors
Published date:
09/28/2020
Excerpt:
...oral ATR inhibitor BAY 1895344 intermittently dosed 5–80 mg twice daily (BID)…One additional patient with BRCA1_Q1401 germline mutation (89% allelic frequency) and high-grade serous ovarian cancer…showed a partial response…(blood CA-125 levels decreasing from 16,693 U/mL at baseline to 6,261 U/mL as best response, which was sustained for more than 28 days), tumor shrinkage (−19% in target lesion size and −50% in lung lesions), and durable stable disease ongoing after 385 days at the time of data cut-off…
DOI:
10.1158/2159-8290.CD-20-0868
Source:
Title:
ELIMUSERTIB, AN ORAL ATAXIA TELANGIECTASIA AND RAD3-RELATED INHIBITOR, IN ADVANCED GYNECOLOGIC CANCERS WITH DNA DAMAGE RESPONSE DEFECTS
Published date:
09/08/2022
Excerpt:
Overall response rate was 2% (1/44 evaluable); 77% of patients had a best response of stable disease. One ovarian cancer patient had a PR lasting 308 days (BRCA1). In ovarian cancer patients, the clinical benefit rate at 120 days was 40%, including patients with previous PARPi treatment; 19% of patients had ≥50% reduction in CA-125 levels....Elimusertib demonstrated clinical benefit in heavily pretreated gynecologic cancers with DDR defects.
